ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

For further information please consult the Company's website at:
www.promisneurosciences.com

Follow us on Twitter

Like us on LinkedIn



Contact Information

For media inquiries, please contact:

 

Scott Santiamo

RussoPartners/LLC

[email protected]

Office: (212) 845-4235

Mobile: (718) 344-5843

[email protected]

 

or contact

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

[email protected]

Latest

Nov 18, 2019, 07:30 ET ProMIS Neurosciences Completes First Closing of Private Placement

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Nov. 18, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...


Nov 14, 2019, 07:30 ET ProMIS Neurosciences Announces Third Quarter 2019 Results

Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease TORONTO and CAMBRIDGE, MA, Nov. 14, 2019 /CNW/ - ProMIS...


Nov 13, 2019, 07:30 ET ProMIS Neurosciences Undertaking $6.5M Private Placement

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, Nov. 13, 2019 /CNW/ - ProMIS Neurosciences, Inc. ("ProMIS" or the "Company") (TSX: PMN;...


Nov 07, 2019, 07:30 ET ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease

Dr. Johanne Kaplan highlights need for precision selectivity for the toxic form of amyloid beta in narrated overview TORONTO and CAMBRIDGE, MA, Nov. 7, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX:...


Oct 24, 2019, 03:00 ET ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease

New resources detail positive impact of aducanumab pivotal trial results and recent progress of ProMIS pipeline programs TORONTO and CAMBRIDGE, MA, Oct. 24, 2019 /CNW/ - ProMIS Neurosciences, Inc....


Oct 23, 2019, 07:30 ET ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43

Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases TORONTO and CAMBRIDGE, MA, Oct. 23, 2019 /CNW/ - ProMIS...


Oct 17, 2019, 07:30 ET ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau

Data show antibody candidates bind toxic forms of tau and inhibit its propagation in a cellular model TORONTO and CAMBRIDGE, MA, Oct. 17, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB:...


Oct 08, 2019, 07:30 ET ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy

Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy TORONTO and CAMBRIDGE, MA, Oct. 8, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX:...


Sep 16, 2019, 07:30 ET ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit

TORONTO and CAMBRIDGE, MA, Sept. 16, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...


Sep 03, 2019, 07:30 ET ProMIS Neurosciences to Present at HC Wainwright Investment Conference

Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs TORONTO and CAMBRIDGE, MA, Sept. 3, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology...


Aug 27, 2019, 07:30 ET ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board

TORONTO and CAMBRIDGE, MA, Aug. 27, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...


Aug 13, 2019, 07:30 ET ProMIS Neurosciences Announces Second Quarter 2019 Results

Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease TORONTO and CAMBRIDGE, MA, Aug. 13, 2019 /CNW/ - ProMIS...


Jul 24, 2019, 07:30 ET ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

ProMIS' shareholders show overwhelming support for all resolutions TORONTO and CAMBRIDGE, MA, July 24, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...


Jul 18, 2019, 15:00 ET ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019

Alzheimer's Association International Conference includes oral session on PMN310 for Alzheimer's disease and poster presentation on ALS TORONTO and CAMBRIDGE, MA, July 18, 2019 /CNW/ - ProMIS...


Jul 10, 2019, 07:30 ET ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference

Abstracts selected for oral and poster presentation TORONTO and CAMBRIDGE, MA, July 10, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the...


Jul 09, 2019, 07:30 ET ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports

Nature Research Journal highlights data supporting the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer's disease TORONTO and CAMBRIDGE, MA,...


Jun 27, 2019, 07:30 ET ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

Data presented at Keystone Symposium on Neurodegenerative Diseases TORONTO and CAMBRIDGE, MA, June 27, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...


Jun 26, 2019, 07:30 ET ProMIS Neurosciences Closing Private Placement

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, June 26, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company...


Jun 19, 2019, 07:30 ET ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board

Internationally recognized leader in neurodegenerative diseases to advise on programs selectively targeting the toxic oligomer TORONTO and CAMBRIDGE, MA, June 19, 2019 /CNW/ - ProMIS Neurosciences,...


Jun 05, 2019, 07:30 ET ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer's disease among world's leading researchers TORONTO and CAMBRIDGE, MA, June...


May 29, 2019, 07:30 ET ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases

TORONTO and CAMBRIDGE, MA, May 29, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics...


May 28, 2019, 07:30 ET ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau

Pipeline offers critical "one-two punch" in potential treatment arsenal for Alzheimer's disease TORONTO and CAMBRIDGE, MA, May 28, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a ...


May 14, 2019, 07:30 ET ProMIS Neurosciences Announces First Quarter 2019 Results

Company continues to show significant progress on developing highly selective antibodies targeting root cause of Alzheimer's and Parkinson's diseases and ALS TORONTO and CAMBRIDGE, MA, May 14, 2019...


Apr 23, 2019, 07:30 ET ProMIS Neurosciences to Participate in the Think Equity Investor Conference

Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs TORONTO and CAMBRIDGE, MA, April 23, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology...


Mar 26, 2019, 07:30 ET ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019

Company to showcase innovative programs addressing urgent need for disease-modifying therapies selectively targeting toxic oligomers in Alzheimer's and Parkinson's diseases and ALS TORONTO and...